Cargando…
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective
BACKGROUND: To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland. METHODS: Administrative claims processed by a major Swiss health insurer between 2005 and 2008 were analysed....
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511873/ https://www.ncbi.nlm.nih.gov/pubmed/23021105 http://dx.doi.org/10.1186/2191-1991-2-20 |